OsimertinibTesting Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Sponsor:

National Cancer Institute (NCI)

Code:

NCT03191149

Conditions

Advanced Lung Non-Small Cell Carcinoma

Recurrent Lung Non-Small Cell Carcinoma

Stage IIIB Lung Non-Small Cell Cancer AJCC v7

Stage IV Lung Non-Small Cell Cancer AJCC v7

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography with Contrast

Echocardiography Test

Magnetic Resonance Imaging

Multigated Acquisition Scan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-23. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-08-04.